Furosemide oral tablet [Regulatives / Guidelines]

posted by Ibrahim Komeil – Egypt, 2019-11-18 09:03 (614 d 06:50 ago) – Posting: # 20818
Views: 944

Dear all

I would like to ask about bioequivalence study for Furosemide oral tablet. It is listed in FDA draft guidance that it is not high variable drug and i can use 2 way crossover design. However, i read EMA guidelines and MHRA guidelines assure its high interasubject variability so they recommend to have partial replicated design applying normal acceptance range (80%-125%), so what do you think about these data upon on your experience ?

Complete thread:

Activity
 Admin contact
21,589 posts in 4,512 threads, 1,530 registered users;
online 19 (0 registered, 19 guests [including 3 identified bots]).
Forum time: Saturday 16:54 CEST (Europe/Vienna)

There are no dangerous thoughts;
thinking itself is dangerous.    Hannah Arendt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5